Ratings by Leerink
| Date | Analyst | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|---|
| 9/1/2026 | David Risinger | Latigo Biotherapeutics | LTGO | New Coverage | Outperform (N/A) |
36.00 (N/A) |
22.02 (22.26) |
1.09% | Details |
| 8/31/2026 | Thomas Smith | Attovia Therapeutics | ATTO | New Coverage | Outperform (N/A) |
52.00 (N/A) |
20.70 (22.22) |
7.34% | Details |
![]() |
|||||||||
![]() |
|||||||||
![]() |
|||||||||
![]() |
|||||||||
![]() |
|||||||||
![]() |
|||||||||
![]() |
|||||||||
![]() |
|||||||||
| 4,155 more... | |||||||||


